Skip to NavigationSkip to content

News

0
Voices in the industry are questioning the EU’s decision to reserve at least 500,000 courses of the therapy on 8 October when it may be of limited...
0
“Based on our current trial enrolment and dosing pace, we estimate we will reach this milestone in the third week of November,” Pfizer CEO Albert...
0
In the event the UK leaves on no-deal terms, there is fear that this could lead to a duplication of standards and regulations across the two...
0
The backing is specific to patients between the ages of six and 11 who are eligible for systemic therapy.

Features

Matt Fellows investigates the new challenges facing the oncology space and explores the strategies that can carry it through the disruptive...